drugset
drugset / Trial / NCT03700294

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

NCT03700294 ↗

Phase 1 Terminated 18 enrolled ADC Therapeutics S.A.
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.

Timeline

Start
2018-12-21
Primary completion
2019-12-11
Completion
2019-12-11

Outcome

Outcome not reported

Stopped: “Change in clinical plan and drug supply”

Drugs

EvaluationDrugModalityDoseRoute
Subject MIPASETAMAB UZOPTIRINE Unknown — Intravenous

Indications

cancer